2025. Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s617. DOI:https://doi.org/10.25251/gf6mb511.